Related Experiment Videos
Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities
Insights
Prostaglandin E1 (PGE1) effectively dilated the ductus arteriosus in infants with aortic arch interruption and coarctation. This improved lower body perfusion and reduced heart failure, offering a crucial intervention for critical congenital heart defects.
Area of Science:
- Pediatric Cardiology
- Neonatal Physiology
- Congenital Heart Disease
Background:
- Infants with aortic arch interruption or juxtaductal coarctation rely on the ductus arteriosus for lower body perfusion.
- Ductal constriction post-birth can lead to severe heart failure, poor perfusion, and acidemia in these infants.
Purpose of the Study:
- To evaluate the efficacy of prostaglandin E1 (PGE1) infusion in maintaining ductal patency.
- To assess the impact of PGE1 on systemic perfusion and cardiac function in neonates with critical aortic arch defects.
Main Methods:
- Prostaglandin E1 (PGE1) was infused at 0.05–0.1 microgram/kg/min in seven infants with aortic arch interruption and eight with coarctation.
- Ductal patency and systemic hemodynamics were monitored, including descending aortic blood pressure and pressure gradients.
Main Results:
- PGE1 effectively dilated the ductus arteriosus in 10 out of 11 eligible infants.
- Improvements observed included increased descending aortic pressures and reduced pressure differences, indicating enhanced lower body perfusion.
- Left ventricular failure symptoms improved in responsive infants.
Conclusions:
- PGE1 infusion is a safe and effective method for maintaining ductal patency in neonates with aortic arch interruption and coarctation.
- Early intervention with PGE1 can significantly improve hemodynamic status and prevent critical complications in affected infants.
Abstract:
Infants with aortic arch interruption of juxtaductal coarctation of the aorta may depend on patency of the ductus arteriosus to provide adequate lower body perfusion. In many such infants the ductus arteriosus constricts after birth, resulting in severe heart failure, poor systemic perfusion and acidemia. We infused prostaglandin E1 (PGE1) at a rate of 0.05--0.1 microgram/kg/min into seven infants with aortic arch interruption and eight infants with coarctation. In one infant in each group the ductus arteriosus was already closed and did not reopen. In one infant with coarctation an adequate trial was not accomplished, and in another adequate pressure measurements were not obtained. Of the remaining 11, the ductus arteriosus was effectively dilated by PGE1 in 10 infants. This was evidenced by an increase in descending aortic blood pressures and a reduction in the pressure difference between the main pulmonary artery and descending aorta in six infants with aortic arch interruption and between ascending and descending aorta in four infants with coarctation. Lower body perfusion improved and left ventricular failure was improved. The infant who did not respond was 5 months old. There were no complications.